These results suggest that combinational treatment with the XPF–ERCC1 blocker can synergistically enhance the therapeutic efficacy of 5-FU- and oxaliplatin-based CRT in colorectal cancer. The gene discussed is ERCC1; the disease is colorectal cancer.